바이오뱅크 시장 : 유형, 컴포넌트, 샘플 유형, 용도, 최종사용자별 - 세계 예측(2026-2032년)

The Biobanks Market is projected to grow by USD 175.29 billion at a CAGR of 11.45% by 2032.

Introduction

Biobanks have become critical infrastructure for precision medicine, drug discovery, population health research, and translational diagnostics. By collecting, processing, storing, and governing human biospecimens alongside linked clinical, genomic, imaging, lifestyle, and longitudinal data, modern biobanks help researchers identify disease mechanisms, validate biomarkers, and develop targeted therapies with stronger real-world relevance.

Demand is being shaped by the expansion of genomics, oncology research, rare disease programs, immunology, regenerative medicine, and public health surveillance. Large-scale initiatives such as UK Biobank, with approximately 500,000 participants, and the U.S. All of Us Research Program, designed to enroll one million or more participants, demonstrate how population-scale biospecimen and data resources are becoming foundational to evidence-based healthcare innovation.

Transformative Shifts in the Biobanks Landscape

The biobanks landscape is shifting from specimen-centered repositories to data-rich, interoperable research platforms. Organizations are prioritizing standardized pre-analytical workflows, automated sample handling, cold-chain integrity, digital consent, and harmonized metadata to improve sample quality and reproducibility across multi-site studies.

A second major shift is the rise of participant-centric and disease-specific biobanking. Patients are increasingly engaged through dynamic consent models, return-of-results discussions, and governance frameworks that emphasize privacy, transparency, and equitable access. This is especially important as biobanks support multi-omics research, real-world evidence generation, and clinical trial matching for precision oncology, cardiometabolic disease, neurodegeneration, and infectious disease studies.

Cumulative Impact of Artificial Intelligence on Biobanks

Artificial intelligence is accelerating the value of biobanks by improving sample annotation, cohort discovery, quality control, and predictive analytics. AI-enabled tools can help researchers identify suitable specimens faster by searching structured and unstructured clinical data, genomic variants, pathology images, and longitudinal outcomes, reducing the time required to build high-quality research cohorts.

The cumulative impact is strongest when AI is paired with robust governance and interoperable data standards. Machine learning can support biomarker discovery, disease-risk modeling, and clinical trial feasibility, but its performance depends on representative datasets, clear provenance, bias monitoring, and privacy-preserving methods such as federated learning. As a result, leading biobanks are investing in data curation, secure analytics environments, and FAIR data principles to ensure AI outputs remain auditable and clinically credible.

Key Regional Insights

North America remains a leading biobanking region due to deep investment in biomedical research, mature academic medical centers, large health systems, and national precision medicine programs. The United States benefits from NIH-supported infrastructure, disease-focused repositories, and large longitudinal programs, while Canada's public health and genomics initiatives support population-level research, Indigenous data governance considerations, and strong ethical oversight.

Europe is distinguished by coordinated research networks, GDPR-driven data protection, and cross-border initiatives that encourage harmonized standards across clinical research and population health. Asia-Pacific is expanding as China, Japan, India, South Korea, Singapore, and Australia build genomic medicine capabilities, national biobank assets, and hospital-linked biospecimen networks. Latin America, the Middle East, and Africa are gaining strategic importance because their diverse populations can improve global disease understanding, although investment in cold-chain infrastructure, consent harmonization, workforce training, and sustainable research funding remains uneven across markets.

Key Group Insights

Within ASEAN, biobanking development is linked to expanding biomedical research capacity, infectious disease surveillance, cancer research, and genomics programs in countries such as Singapore, Thailand, Malaysia, Indonesia, and Vietnam. The GCC is investing in precision medicine and population health as part of broader healthcare modernization, with national genome initiatives, academic medical partnerships, and health data strategies supporting biobank development.

The European Union provides one of the most structured environments for cross-border biobank collaboration through data protection rules, research funding frameworks, and infrastructure networks that promote interoperability and ethical access. BRICS countries are important because they combine large populations, genetic diversity, and rising biotechnology investment, although regulatory maturity and data-sharing practices vary. G7 countries continue to set benchmarks in data governance, translational research, and pharmaceutical partnerships, while NATO countries increasingly recognize biobanking relevance for biodefense, public health resilience, and pandemic preparedness.

Key Country Insights

The United States leads through extensive NIH-funded repositories, cancer and rare disease collections, academic medical centers, and the All of Us Research Program. Canada emphasizes population health, ethics, and genomics collaboration, while Mexico and Brazil are strengthening cancer, infectious disease, and population diversity research. In Europe, the United Kingdom's UK Biobank is a global reference model, while Germany, France, Italy, and Spain maintain strong clinical research networks, population cohorts, and disease-specific repositories; Russia has scientific capacity but faces more complex international collaboration dynamics.

China is scaling biobanking through major hospitals, genomics research, and national precision medicine priorities, while India's large and diverse population creates significant opportunity for population genomics, newborn screening research, and disease-specific repositories. Japan and South Korea are advanced in precision medicine, aging research, oncology, and high-quality clinical data integration. Australia combines population health expertise, longitudinal cohorts, Indigenous health governance considerations, and strong research ethics frameworks, supporting its role as a major Asia-Pacific biobanking hub.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biospecimen quality, standardized operating procedures, and interoperable metadata because sample integrity directly affects downstream research reliability. Investments in laboratory automation, temperature monitoring, chain-of-custody systems, validated storage protocols, and internationally recognized quality management practices can reduce variability and improve trust among academic, clinical, and pharmaceutical partners.

Executives should also strengthen data governance by adopting dynamic consent, privacy-by-design architecture, controlled access committees, and transparent benefit-sharing practices. To compete in AI-enabled biobanking, organizations should build secure analytics environments, curate high-quality linked datasets, align with FAIR principles, and develop partnerships with hospitals, contract research organizations, diagnostics developers, and biopharmaceutical companies.

Research Methodology

This executive summary is based on secondary research from publicly available biomedical research programs, government health agencies, peer-reviewed literature, national genomics initiatives, regulatory frameworks, and documented biobank infrastructure models. The assessment emphasizes verifiable indicators such as established population cohorts, national precision medicine programs, recognized data governance requirements, ethical guidelines, and documented regional healthcare investment patterns.

The methodology applies qualitative triangulation across scientific, regulatory, operational, and commercial sources to identify consistent trends in biobanking demand, technology adoption, AI integration, and geographic expansion. Insights are structured to support strategic planning for biobank operators, pharmaceutical companies, academic research centers, healthcare systems, diagnostics firms, and investors evaluating the global biobanks landscape without relying on market sizing, market share, or forecasting assumptions.

Conclusion

Biobanks are evolving into strategic engines for precision medicine, data-driven drug development, and population health intelligence. Their value increasingly depends on the ability to combine high-quality biospecimens with validated clinical data, advanced analytics, ethical governance, and scalable collaboration models.

Organizations that invest in automation, AI-ready data infrastructure, global standards, and participant trust will be best positioned to capture long-term opportunities. As genomics, multi-omics, and real-world evidence become central to healthcare innovation, biobanks will remain indispensable to the future of biomedical discovery and personalized care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biobanks Market, by Type

• 7.1. Disease-Oriented Biobanks
• 7.2. Genomic-Based Biobanks
• 7.3. Population-Based Biobanks
• 7.4. Virtual Biobanks

8. Biobanks Market, by Component

• 8.1. Consumables
• 8.2. Equipment
  • 8.2.1. Incubators & Centrifuges
  • 8.2.2. Monitoring Systems
  • 8.2.3. Temperature Control Systems
    • 8.2.3.1. Cryogenic Storage Systems
    • 8.2.3.2. Freezers & Refrigerators
    • 8.2.3.3. Thawing Equipment
• 8.3. Services
  • 8.3.1. Data Management
  • 8.3.2. Sample Analysis
  • 8.3.3. Storage & Processing
  • 8.3.4. Transport

9. Biobanks Market, by Sample Type

• 9.1. Blood Derivatives
• 9.2. Cell Lines
• 9.3. Nucleic Acid
• 9.4. Tissues

10. Biobanks Market, by Application

• 10.1. Clinical Diagnostics
• 10.2. Personalized Medicine
• 10.3. Research
• 10.4. Therapeutics
  • 10.4.1. Drug Development
  • 10.4.2. Gene Editing

11. Biobanks Market, by End User

• 11.1. Academic Institutions
• 11.2. Contract Research & Manufacturing Organizations
• 11.3. Hospitals
• 11.4. Pharmaceutical & Biotech Companies

12. Biobanks Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Biobanks Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Biobanks Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Acorn Biolabs Inc.
• 16.2. Anuva
• 16.3. ASKION GmbH
• 16.4. Avantor, Inc.
• 16.5. Azenta Life Science
• 16.6. Bay Biosciences LLC
• 16.7. Beckman Coulter, Inc. by Danaher Corporation
• 16.8. Becton, Dickinson and Company
• 16.9. BioIVT, LLC
• 16.10. BioKryo by L'AIR LIQUIDE S.A.
• 16.11. BioLife Solutions Inc.
• 16.12. BocaBio
• 16.13. Bruker Corporation
• 16.14. CELLIVIA 3 S.A.
• 16.15. Celltex Therapeutics Corporation
• 16.16. Charles River Laboratories International, Inc.
• 16.17. Cryoport Systems, LLC
• 16.18. CTIBiotech by Swedish Orphan Biovitrum AB
• 16.19. Cureline, Inc
• 16.20. Firalis Group
• 16.21. Greiner Bio-One International GmbH
• 16.22. Hamilton Company
• 16.23. Hope Biosciences, LLC
• 16.24. Lonza Group Ltd.
• 16.25. LVL technologies GmbH & Co. KG.
• 16.26. Merck KGaA
• 16.27. Precision Cellular Storage Ltd.
• 16.28. ProteoGenex, Inc.
• 16.29. Provia Laboratories, Inc.
• 16.30. Qiagen N.V.
• 16.31. Standard BioTools Inc.
• 16.32. STEMCELL Technologies
• 16.33. Tecan Trading AG
• 16.34. Thermo Fisher Scientific Inc.
• 16.35. UK Biobank Limited